Top

Published in:

01-07-2023 | Sulfonylurea | Clinical study

Sulfonylurea-DPP-4 inhibitor combination: risk of hypoglycaemia similar for all combinations

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Intra-class pharmacological heterogeneity among sulfonylureas (based on duration of action) and among dipeptidyl peptidase-4 (DPP-4) inhibitors (based on chemical structure) does not modify the risk of severe hypoglycaemia with concomitant use of these medicines. …

Dimakos J, et al. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study. Clinical Pharmacology and Therapeutics : 16 Jun 2023. Available from: URL: http://doi.org/10.1002/cpt.2975

Title: Sulfonylurea-DPP-4 inhibitor combination: risk of hypoglycaemia similar for all combinations
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Sulfonylurea
Hypoglycemia
Glimepiride
Glibenclamide
Glipizide
Saxagliptin
Vildagliptin
Gliclazide
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42067-x

At a glance: The STEP trials

Springer Medicine

Sulfonylurea-DPP-4 inhibitor combination: risk of hypoglycaemia similar for all combinations

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Desmopressin

Amlodipine/antibacterials/immunosuppressants

Hydroxycarbamide/ixekizumab

Eculizumab

Tozinameran

Methotrexate/oseltamivir